Cancer News and Research

Latest Cancer News and Research

Public need to be informed of nanotechnology's risks as well as benefits: Survey

A new national survey on public attitudes toward medical applications and physical enhancements that rely on nanotechnology shows that support for the technology increases when the public is informed of the technology's risks as well as its benefits - at least among those people who have heard of nanotechnology.

6 May 2010

Momenta Pharmaceuticals first-quarter net loss decreases to $16.1 million

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2010.

6 May 2010

Investigators demonstrate safety and efficacy of targeted medication to shrink advanced kidney cancers

A multicenter team of investigators led by the University of California, San Diego School of Medicine has demonstrated, for the first time, the safety and efficacy of a targeted medication to shrink advanced kidney cancers prior to partial kidney removal and reconstruction. Their findings were published in the April 2010 online edition of BJU International.

6 May 2010

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

6 May 2010

CombinatoRx reports $41.3M total revenue for first-quarter 2010

CombinatoRx, Incorporated today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

ArQule reports net loss of $9,752,000 for first-quarter 2010

ArQule, Inc. today announced its financial results for the first quarter of 2010.

6 May 2010

Study aims to clarify expression patterns of CD24 in NSCLC

The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance.

6 May 2010

Swedish Cancer Institute, Elekta renew partnership to continue flow of technology, services to cancer patients

Swedish Cancer Institute and Elekta launch renewed partnership agreement to continue the flow of world-class technology, services to cancer patients in the Pacific Northwest and beyond.

From Elekta 6 May 2010

Vical reports net loss of $8.5 million for first-quarter 2010

Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.

6 May 2010

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

A prescription drug already approved to treat genital warts and skin cancer may have a new use in boosting the effectiveness of future vaccines for bacterial and viral diseases, such as hepatitis C and HIV (the AIDS virus). These findings appear in ACS' Molecular Pharmaceutics, a bi-monthly journal.

6 May 2010

Scientists analyze genetic networks of microRNAs in tumors

Genes interact in complex networks that govern cellular processes, much like people connect a social network through relationships. Researchers are now discovering how biological networks change and are rewired in cancer.

6 May 2010

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

BioInvent International AB and ThromboGenics NV announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

6 May 2010

Study confirms long-term durability of endoscopic RFA using HALO system for eradicating Barrett's esophagus

Results from two major multi-center clinical trials presented at the Digestive Disease Week in New Orleans independently confirmed that the effects of endoscopic radiofrequency ablation (RFA) for eradicating a pre-cancerous condition of the esophagus called Barrett's esophagus are durable in the long-term. In a plenary scientific presentation titled "Endoscopic Radiofrequency Ablation for Barrett's Esophagus: Five-year Durability Outcomes from a Prospective Multi-Center Trial," patients with Barrett's esophagus were treated with endoscopic RFA using the HALO system.

6 May 2010

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

New research by scientists at The University of Texas Health Science Center at Houston (UTHealth) and The University of Texas M. D. Anderson Cancer Center could make it easier for patients to use a family of promising experimental cancer therapeutics known as small interfering RNA (siRNA).

6 May 2010

Round-up: Minnesota budget news; Coverage expansions in S.D. and Oregon; and states' opposition to federal health reform

The Minnesota House passed a bill on health care Tuesday that readies the state for implementing the federal health care overhaul and makes $170 million in cuts to mental health and other social programs, The (St. Paul, Minn.) Pioneer Press reports. Gov. Tim Pawlenty has promised to veto the bill over what he sees as a tax increase.

6 May 2010

Ovarian hormone progesterone plays pivotal role in altering breast stem cells: PMH researchers

Cancer researchers at Princess Margaret Hospital have discovered that the ovarian hormone progesterone plays a pivotal role in altering breast stem cells, a finding that has important implications for breast cancer risk.

6 May 2010

VEGF is key target for new anti-angiogenesis drugs, Spanish team reports

Analyzing the expression of particular genes in lung cancers could soon allow researchers to identify groups of patients who are likely to benefit most from treatment with angiogenesis-inhibitor drugs, a Spanish team reports.

6 May 2010

Colonoscopy preparation drugs administered same day as procedure equally effective: Researchers

Researchers at Thomas Jefferson University have found that colonoscopy preparation drugs administered the same day as the procedure are equally effective to those given the night before and the morning of the procedure, but result in less complaints of side effects such as abdominal pain, sleep loss and workday interference.

6 May 2010

New blood test could increase success of lung cancer drug erlotinib: Study

A new blood test could increase the success of a popular lung cancer drug called erlotinib by allowing doctors select which patients will react positively to the drug.

6 May 2010

Research reveals role of ovarian hormone progesterone in alteration of breast stem cells

Cancer researchers at Princess Margaret Hospital (PMH) have discovered that the ovarian hormone progesterone plays a pivotal role in altering breast stem cells, a finding that has important implications for breast cancer risk.

6 May 2010

Cancer News and Research

Latest Cancer News and Research

Public need to be informed of nanotechnology's risks as well as benefits: Survey

Momenta Pharmaceuticals first-quarter net loss decreases to $16.1 million

Investigators demonstrate safety and efficacy of targeted medication to shrink advanced kidney cancers

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

CombinatoRx reports $41.3M total revenue for first-quarter 2010

ArQule reports net loss of $9,752,000 for first-quarter 2010

Study aims to clarify expression patterns of CD24 in NSCLC

Swedish Cancer Institute, Elekta renew partnership to continue flow of technology, services to cancer patients

Vical reports net loss of $8.5 million for first-quarter 2010

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

Scientists analyze genetic networks of microRNAs in tumors

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

Study confirms long-term durability of endoscopic RFA using HALO system for eradicating Barrett's esophagus

Multistage nanovector system for siRNA delivery lengthens therapeutic effects of ovarian cancer treatment

Round-up: Minnesota budget news; Coverage expansions in S.D. and Oregon; and states' opposition to federal health reform

Ovarian hormone progesterone plays pivotal role in altering breast stem cells: PMH researchers

VEGF is key target for new anti-angiogenesis drugs, Spanish team reports

Colonoscopy preparation drugs administered same day as procedure equally effective: Researchers

New blood test could increase success of lung cancer drug erlotinib: Study

Research reveals role of ovarian hormone progesterone in alteration of breast stem cells

Understanding the DNA Damage Response in Innate Immunity eBook

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Newsletters you may be interested in